Eine Kostenanalyse von Telithromycin im Vergleich zu Clarithromycin und Amoxicillin/Clavulansäure in der Behandlung von Patienten mit ambulant erworbener Pneumonie oder akuter Exazerbation einer chronischen Bronchitis in ÖsterreichCost analysis of telithromycin versus clarithromycin and amoxicillin/clavulanic acid in the treatment of patients with community-acquired pneumonia or acute exacerbations of chronic bronchitis

Background Lower respiratory tract infections (LRTI) such as community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB) are frequent diseases associated with high morbidity and mortality. The use of antibiotics faces growing challenges due to resistance problems. Telithromycin is a new antibacterial agent of the ketolide class designed to provide optimal treatment against common bacterial respiratory tract pathogens. The aim of this study was to compare telithromycin with clarithromycin and amoxicillin/clavulanic acid, the standard antibacterial treatments for CAP or AECB in Austria, with regard to costs and treatment outcomes.